Outlook Therapeutics/$OTLK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Outlook Therapeutics
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Ticker
$OTLK
Sector
Primary listing
Employees
23
Headquarters
Website
OTLK Metrics
BasicAdvanced
$89M
-
-$1.79
-
-
Price and volume
Market cap
$89M
52-week high
$3.39
52-week low
$0.79
Average daily volume
4.7M
Financial strength
Total debt to equity
-93.299
Interest coverage (TTM)
-236.97%
Profitability
EBITDA (TTM)
-66.946
Gross margin (TTM)
4.03%
Net profit margin (TTM)
-4,417.91%
Operating margin (TTM)
-4,746.07%
Effective tax rate (TTM)
2.43%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on equity (TTM)
113.23%
Valuation
Price to revenue (TTM)
49.498
Price to book
-2.35
Price to tangible book (TTM)
-2.35
Growth
Earnings per share change (TTM)
-55.85%
10-year revenue growth (CAGR)
-12.25%
3-year earnings per share growth (CAGR)
-33.96%
10-year earnings per share growth (CAGR)
-46.12%
What the Analysts think about OTLK
Analyst ratings (Buy, Hold, Sell) for Outlook Therapeutics stock.
OTLK Financial Performance
Revenues and expenses
OTLK Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Outlook Therapeutics stock?
Outlook Therapeutics (OTLK) has a market cap of $89M as of December 20, 2025.
What is the P/E ratio for Outlook Therapeutics stock?
The price to earnings (P/E) ratio for Outlook Therapeutics (OTLK) stock is 0 as of December 20, 2025.
Does Outlook Therapeutics stock pay dividends?
No, Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders as of December 20, 2025.
When is the next Outlook Therapeutics dividend payment date?
Outlook Therapeutics (OTLK) stock does not pay dividends to its shareholders.
What is the beta indicator for Outlook Therapeutics?
Outlook Therapeutics (OTLK) does not currently have a Beta indicator.